OpenAI Invests in Startup That Uses Brain Implants to Detect Cancer
OpenAI's venture capital arm and Peter Thiel's Founders Fund are investing $45 million in Coherence Neuro, a startup developing brain implants and AI models to detect and treat cancer.
Intelligence analysis by Gemini 2.5 Flash
The investment highlights a growing trend of Big Tech and AI labs showing interest in brain data and brain-computer interfaces (BCIs). Coherence Neuro aims to use AI to decode subtle electrical signals associated with brain tumors, with plans to develop implants that can both detect and provide real-time electrical stimulation to halt tumor growth.
Imagine your brain sends out tiny secret messages, like a special code, when something like cancer is happening. This company, Coherence Neuro, is making a tiny computer chip to put in your brain that can listen to these messages. Then, a super-smart computer brain, called AI, helps understand what those messages mean, like a detective cracking a code. The goal is for the chip to not only find cancer early but also send out little zaps to stop it from growing, like a tiny superhero fighting bad guys inside your head.
Analysis
Coherence Neuro
Coherence Neuro, a San Francisco-based startup, is at the forefront of integrating artificial intelligence with brain-computer interfaces to tackle aggressive diseases like cancer. Unlike many BCI companies that focus on restoring function for paralyzed individuals, Coherence is specifically developing AI models to interpret subtle electrical signals linked to brain tumors. The company claims to have already achieved success in detecting these signals in animals, discerning whether cancer is progressing, regressing, or recurring.
The startup's ambitious goal is to translate these animal findings into human research and, eventually, clinical trials. Their device is designed not only for detection but also for therapeutic intervention, capable of emitting mild electrical stimulation to inhibit tumor growth. The long-term vision involves the implant continuously learning to identify cancer-related signals and delivering real-time, adaptive treatment, marking a significant leap in personalized cancer therapy.
Ben Woodington
Ben Woodington, CEO and cofounder of Coherence Neuro, emphasizes the increasing synergy between major AI laboratories and companies developing brain-computer interfaces. He views AI as an ideal application for BCI technology, primarily because these devices generate vast datasets that are too complex and voluminous for human analysis alone. Woodington believes that AI models are crucial for interpreting raw neural data and correlating it with specific actions or biological states, such as tumor activity.
Woodington also addressed concerns regarding data privacy and access, stating unequivocally that OpenAI will not have access to Coherence Neuro's brain or health data. He clarified that no contractual agreements or arrangements permit such sharing, distinguishing this relationship from OpenAI's collaboration with Merge Labs, where OpenAI explicitly stated it would "collaborate with Merge Labs on scientific foundation models and other frontier tools."
Royal Melbourne Hospital
Coherence Neuro has already taken initial steps into human testing, conducting brief trials at the Royal Melbourne Hospital in Australia. During these trials, the recording capabilities of its implant were tested in the brains of three patients who were undergoing brain tumor removal surgery. The implant remained in place for approximately 30 minutes before removal, serving as an initial safety assessment.
Following this preliminary safety check, Coherence plans to expand its human research by testing both the recording and stimulation functionalities of the device in an additional seven patients. The new $45 million seed funding round, which includes investments from OpenAI's venture arm and Peter Thiel's Founders Fund, is earmarked to launch a full clinical trial. This trial will involve long-term implantation of the device in patients suffering from glioblastoma, a particularly aggressive form of brain cancer, with future aspirations to target cancers in other parts of the body.
Key points
- OpenAI's venture arm and Founders Fund invested $45 million in Coherence Neuro, a brain implant startup.
- Coherence Neuro is developing AI-powered brain implants to detect and treat cancer by decoding neural signals.
- The company has successfully detected cancer signals in animals and conducted initial safety tests in human patients at Royal Melbourne Hospital.
- The implants are designed to both record signals associated with tumors and emit electrical stimulation to halt their growth.
- New funding will support a clinical trial for long-term implantation in glioblastoma patients, with future plans for other body cancers.
This development could lead to revolutionary advancements in cancer treatment, enabling earlier detection and highly personalized, real-time interventions directly at the source of brain tumors. The integration of AI with brain implants holds the potential to significantly improve patient outcomes and quality of life for those battling aggressive cancers.
The use of brain implants carries inherent risks, including surgical complications, potential for infection, and long-term safety concerns regarding device malfunction or unforeseen neurological impacts. Ethical considerations around brain data privacy and the potential for over-reliance on AI in critical medical decisions also present significant challenges.
